Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Free Cash Flow (2022 - 2025)

Historic Free Cash Flow for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to -$18.8 million.

  • BioXcel Therapeutics' Free Cash Flow fell 1498.96% to -$18.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$58.2 million, marking a year-over-year increase of 3076.44%. This contributed to the annual value of -$72.0 million for FY2024, which is 5353.88% up from last year.
  • As of Q3 2025, BioXcel Therapeutics' Free Cash Flow stood at -$18.8 million, which was down 1498.96% from -$12.6 million recorded in Q2 2025.
  • Over the past 5 years, BioXcel Therapeutics' Free Cash Flow peaked at -$12.0 million during Q1 2025, and registered a low of -$52.4 million during Q1 2023.
  • Its 4-year average for Free Cash Flow is -$27.1 million, with a median of -$26.9 million in 2023.
  • Its Free Cash Flow has fluctuated over the past 5 years, first tumbled by 6092.28% in 2023, then surged by 6617.96% in 2024.
  • BioXcel Therapeutics' Free Cash Flow (Quarter) stood at -$38.6 million in 2022, then surged by 30.48% to -$26.9 million in 2023, then soared by 44.87% to -$14.8 million in 2024, then dropped by 26.86% to -$18.8 million in 2025.
  • Its last three reported values are -$18.8 million in Q3 2025, -$12.6 million for Q2 2025, and -$12.0 million during Q1 2025.